TNF Inhibitor denied due to quantity / dose limits by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Imposes Quantity Limits on TNF Inhibitors

Anthem Blue Cross applies quantity limits (QL) to TNF inhibitors as part of its formulary management — restricting the number of doses, vials, or injection devices dispensed per fill or per time period to align with what its clinical policy considers standard dosing. A quantity-limit denial means the quantity prescribed exceeds the plan's authorized limit, even if the prescriber has a clinically sound reason for the higher quantity.

Quantity-limit denials are frequently appealed successfully when there is documented clinical justification for the non-standard quantity — such as a dose adjustment within the FDA-labeled dosing range, a dosing schedule for a different indication, or a supply requirement for patient-specific circumstances (travel, access, adherence).

## Federal Appeal Framework

• Quantity exception / PA for quantity override: Before a formal appeal, ask the prescribing office to submit a quantity exception or a PA specifically for the requested quantity, with clinical justification.
• Internal appeal (ERISA §503 / ACA §2719): If the exception is denied, file a formal internal appeal within the deadline on your denial letter, with documentation supporting the prescribed quantity.
• External independent review: Available on ACA-compliant plans after internal exhaustion. The window is generally up to approximately four months from final internal denial.
• Expedited review: If a delay creates a serious health risk (e.g., treatment interruption).

## Documentation to Gather

1. Prescriber's dosing rationale — a written statement from the clinician explaining the prescribed quantity, referencing the FDA-approved prescribing information for the dosing range and the clinical basis for this patient's specific regimen. 2. Diagnosis and indication — chart notes and ICD codes confirming the approved indication, since some indications have different dosing frequencies within the same FDA label. 3. FDA prescribing label — identify the dosing range, frequency, and indication-specific schedules in the current label, and confirm the prescribed quantity is within it. 4. Prior response history — if dose was escalated due to inadequate response, document prior dosing levels, response assessment dates, and the clinical finding that prompted the change. 5. Anthem's quantity-limit policy — retrieve the exact QL value and the override criteria from Anthem's published drug coverage policy or formulary documents.

## Criteria-Mapping Structure

| Anthem Quantity-Limit Override Criterion | Supporting Documentation | |---|---| | [Copy each override requirement verbatim from Anthem's policy] | [FDA label section, chart note date, and clinician statement addressing each] |

Your prescriber's letter should: - Cite the relevant section of the FDA-approved prescribing label showing the dosing range that supports the requested quantity - Reference the applicable guideline organization's dosing recommendation for the diagnosis - Explain the individual clinical rationale for the quantity prescribed

Never rely on remembered dose amounts or thresholds. Verify all quantities and clinical criteria against the current FDA prescribing label and Anthem's current published formulary/quantity-limit policy before submitting.